Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon Acquired Resistance to Osimertinib?
By
GRACE
FEATURING
Zofia Piotrowska
By
GRACE
FEATURING
Zofia Piotrowska
Login to view comments.
Click here to Login
Videos